| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Bazedoxifene acetate (JAN/USAN); Viviant (TN) | ||||||||
| Formula | C30H34N2O3. C2H4O2 | ||||||||
| Exact mass | 530.2781 | ||||||||
| Mol weight | 530.6545 | ||||||||
| Structure |  | ||||||||
| Class | Hormonal agent DG01619 Estrogen receptor antagonist/modulator DG01621 Selective estrogen receptor modulator Musculo-skeletal system agent DG03232 Osteoporosis agent | ||||||||
| Remark |
| ||||||||
| Efficacy | Osteoporosis agent, Selective estrogen receptor modulator (SERM) | ||||||||
| Comment | Benzothiophene derivative Prevention or treatment of osteoporosis | ||||||||
| Target | NR3A (ESR) [HSA:2099 2100] [KO:K08550 K08551] | ||||||||
| Pathway |
| ||||||||
| Interaction | |||||||||
| Structure map |
| ||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] G GENITO URINARY SYSTEM AND SEX HORMONES G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM G03XC Selective estrogen receptor modulators G03XC02 Bazedoxifene D03062 Bazedoxifene acetate (JAN/USAN) <JP> Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 39 Other agents affecting metabolism 399 Miscellaneous 3999 Others D03062 Bazedoxifene acetate (JAN/USAN) Drug groups [BR:br08330] Hormonal agent DG01619 Estrogen receptor antagonist/modulator DG01621 Selective estrogen receptor modulator D03062 Bazedoxifene acetate Musculo-skeletal system agent DG03232 Osteoporosis agent D03062 Bazedoxifene acetate Drug classes [BR:br08332] Musculo-skeletal system agent DG03232 Osteoporosis agent D03062 Bazedoxifene acetate Target-based classification of drugs [BR:br08310] Nuclear receptors Estrogen like receptors Estrogen receptor NR3A (ESR) D03062 Bazedoxifene acetate (JAN/USAN) <JP> New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D03062 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D03062 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D03062 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 39 1 C1a C 28.3500 -22.8200 2 C6a C 29.5400 -22.1200 3 O6a O 30.7300 -22.8200 4 O6a O 29.5400 -20.7200 5 C8y C 15.7500 -21.4900 6 C8x C 15.7500 -22.8900 7 C8x C 16.9400 -23.5900 8 C8y C 18.2000 -22.8900 9 C8x C 18.2000 -21.4900 10 C8x C 16.9400 -20.7900 11 O2a O 19.3900 -23.5900 12 C1b C 20.5800 -22.8900 13 C1b C 21.7700 -23.5900 14 N1y N 22.9600 -22.8900 15 C1b C 14.5600 -20.7900 16 N4y N 13.3700 -21.4900 17 C8y C 12.2500 -20.7200 18 C8y C 11.1300 -21.4900 19 C8y C 11.5500 -22.8200 20 C8y C 12.9500 -22.8200 21 C8x C 10.9200 -24.0100 22 C8y C 11.6200 -25.2000 23 C8x C 13.0200 -25.2000 24 C8x C 13.6500 -24.0100 25 C1x C 22.9600 -21.4900 26 C1x C 24.0800 -20.5800 27 C1x C 25.4100 -20.9300 28 C1x C 26.0400 -22.1900 29 C1x C 25.4100 -23.4500 30 C1x C 24.0800 -23.7300 31 O1a O 10.9249 -26.4153 32 C8y C 12.2500 -19.3200 33 C1a C 9.8061 -21.0346 34 C8x C 13.4624 -18.6200 35 C8x C 13.4624 -17.2200 36 C8y C 12.2500 -16.5200 37 C8x C 11.0376 -17.2200 38 C8x C 11.0376 -18.6200 39 O1a O 12.2500 -15.1200 BOND 42 1 1 2 1 2 2 3 1 3 2 4 2 4 5 6 2 5 6 7 1 6 7 8 2 7 8 9 1 8 9 10 2 9 5 10 1 10 8 11 1 11 11 12 1 12 12 13 1 13 13 14 1 14 5 15 1 15 15 16 1 16 16 17 1 17 17 18 2 18 18 19 1 19 19 20 1 20 16 20 1 21 19 21 2 22 21 22 1 23 22 23 2 24 23 24 1 25 20 24 2 26 27 28 1 27 25 14 1 28 28 29 1 29 26 27 1 30 25 26 1 31 29 30 1 32 30 14 1 33 22 31 1 34 17 32 1 35 18 33 1 36 32 34 2 37 34 35 1 38 35 36 2 39 36 37 1 40 37 38 2 41 32 38 1 42 36 39 1 |